Latest news with #AstecLifeSciences
&w=3840&q=100)
Business Standard
14 hours ago
- Business
- Business Standard
This smallcap stock rallies 6% as board to consider fundraising on June 24
Astec LifeSciences share price: Chemical manufacturing company Astec LifeSciences shares zoomed up to 5.94 per cent to hit an intraday high of ₹784.65 per share on Friday, June 20, 2025. By 11:40 AM, Astec LifeSciences shares were off day's high, but continued to trade 2.30 per cent higher at ₹757.70. In comparison, BSE Sensex was up 0.88 per cent at 82,081.23 levels. Catch Stock Market LIVE Updates Today Why did Astec LifeSciences share price jump in trade today? Astec LifeSciences shares rose after the company announced that its board will meet on June 24 to consider the proposal of fund raising via equity shares or any other securities through appropriate mode including rights issue. In an exchange filing, Astec LifeSciences said, 'This is to inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, June 24, 2025 to consider, inter alia, the proposal of fund raising by way of Equity Shares or any other securities through appropriate mode including rights issue, as may be permitted under applicable law and as may be decided by the Board, subject to such regulatory/statutory approvals as may be required.' Astec LifeSciences Q4 results Astec LifeSciences reported a consolidated total income of ₹120.3 crore for Q4FY25, down from ₹155.8 crore in Q4FY24. On a sequential basis, total income rose 25.6 per cent compared to Q3FY25. Consolidated Ebitda stood at ₹6.3 crore in Q4FY25, lower than ₹14.8 crore in the year-ago quarter. However, it marked an improvement over Q3FY25 levels. N B Godrej, chairman, Astec LifeSciences Limited, said, 'In Q4FY25, Astec reported sequential improvement in performance. Ebitda for Q4FY25 at ₹6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to increase in volumes and prices in Enterprise business coupled with improved product mix in the CDMO business. We expect an uptick in the demand for Enterprise & CDMO businesses and a gradual improvement in the performance in the coming year.' ALSO READ | About Astec LifeSciences Established in 1994, Astec LifeSciences (Astec) is engaged in the production of agrochemical active ingredients (technicals), bulk formulations, and intermediate products. The company maintains a balanced sales mix between domestic and export markets, with exports spanning over 17 countries, including the United States, and regions such as Europe, West Asia, South-East Asia, Latin America, and Africa.
Business Standard
24-04-2025
- Business
- Business Standard
Astec Life tumbles after Q4 net loss widens to Rs 16 cr
Astec Lifesciences dropped 2.73% to Rs 748.60 after the company's consolidated net loss widened to Rs 16.08 crore in Q4 FY25 as against a net loss of Rs 0.964 crore reported in Q4 FY24. Revenue from operations declined 22.26% YoY to Rs 119.53 crore in the quarter ended 31 March 2025. Loss before tax stood at Rs 15.66 crore in Q4 FY25, widening from a loss of Rs 0.93 crore in the same period last year. EBITDA came in at Rs 6.32 crore in Q4 FY25, down 57.18% from Rs 14.76 crore reported in Q4 FY24. Total expense tanked 13.23% year on year to Rs 135.98 crore during the quarter. The cost of materials consumed was Rs 85.45 crore (up 3.58% YoY), while employee benefits expense stood at Rs 14.43 crore (down 1.77% YoY) during the period under review. On the margins front, operating margin narrowed to 4.62% in Q4 FY25, compared to 8.27% in Q4 FY24. N. B. Godrej, chairman of Astec LifeSciences, said, In Q4 FY25, Astec reported sequential improvement in performance. EBITDA for Q4 FY25 at Rs 6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to an increase in volumes and prices in the enterprise business coupled with an improved product mix in the CDMO business. We expect an uptick in the demand for enterprise & CDMO businesses and a gradual improvement in the performance in the coming year. Astec Lifesciences is into the manufacturing of agrochemical active ingredients (technical), bulk and formulations, and intermediate products, and it sells its products in India as well as exports them to approximately 24 countries.
